Harrow posts record Q3 revenue, cuts 2026 Adjusted EBITDA outlookNov 9Quarterly updatechloroprocaine hydrochloride ophthalmic gelHarrow Inc
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Harrow completes TYRVAYA acquisition from Viatris, excluding Japan rightsOct 5Regulatory decisionHarrow Incvarenicline
Harrow to acquire global rights to TYRVAYA nasal spray from ViatrisAug 6Regulatory decisioncyclosporine ophthalmic solutionHarrow Inc
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 updateAug 6Quarterly updatevareniclineViatris Inc.
Mylan doxepin label update approved; Viatris-linked contact lens comfort trial begins recruitingJul 16Weekly roundup, 2 itemsdoxepinViatris Inc.